^
Association details:
Biomarker:REST signature
Cancer:Glioblastoma
Drug:linsitinib (ASP7487) (IGF-1R inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

An expression based REST signature predicts patient survival and therapeutic response for glioblastoma multiforme

Excerpt:
...we developed an expression based REST signature and assessed its association with transcriptomics, genomics, drug sensitivity and clinical outcome for GBM in this article....Linsitinib, an IGF1R inhibitor...emerged as the top hit associated with enhanced activity in REST-high cell lines (Fig. 4A).
DOI:
10.1038/srep34556